US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have yet to make a significant dent in global infections. "This is a historic day in the decades-long fight against HIV," Gilead chairman and chief executive Daniel O'Day said in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine. The company conducted two large clinical trials. The first, involving more than 2,000 women in sub-Saharan Africa, resulted in a 100 percent reduction in infections and demonstrated superiority over the daily oral pill Truvada.
In the second trial, involving over 2,000 men and gender-diverse individuals, only two infections were recorded - a 99.9 percent prevention rate, again surpassing Truvada. Reported side effects included injection site reactions, headache, and nausea. Results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 "Breakthrough of the Year."
Price concerns dampen hope
Despite the impressive results, optimism may be tempered by the drug's cost -- a list price of $28,218 per year in the United States, Gilead spokeswoman Blair Baumwell told AFP in an email Wednesday.
An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact.
Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually.
Baumwell said the $28,000-plus per year cost for Lenacapavir as a preventive drug is "in line with" those of existing PrEP products and that the company inspects insurers to cover it.
"We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage," she said in the email. Activists are urging Gilead to drastically cut the price to help end the HIV pandemic.
"Even high-income countries will not be able to afford widescale use of lenacapavir at prices above US $20,000 per year," said Andrew Hill of Liverpool University, who led a team of chemists and scientists that found it could be mass-produced and sold for as little as $25 per person per year.
"I congratulate Gilead and US partners for advancing this important innovation," added Winnie Byanyima, under-secretary-general of the United Nations. "Lenacapavir could be the tool we need to bring new infections under control -- but only if it is priced affordably and made available to everyone who could benefit."
In October, Gilead signed agreements with six pharmaceutical companies to produce and distribute generic versions of the drug, pending regulatory approval, in 120 low- and middle-income countries.
Because it will take time for those countries to begin production, the company also announced a separate deal in December with the Global Fund -- an international partnership established by the United Nations, alongside the US President's Emergency Plan for AIDS Relief (PEPFAR) and others -- to purchase doses for two million people.
However, cuts to the PEPFAR program under President Donald Trump's administration have cast uncertainty over the future of that agreement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
A shot of hope
New HIV medicine is powerful – but can everyone afford it? A new medicine called lenacapavir has just been approved in the US to help stop people from getting HIV, the virus that causes AIDS. That's big news! Even though fewer people are getting HIV today than in the 1990s, around 13 lakh (1.3 million) people still get infected every year around the world. Lenacapavir is special because you only need two shots a year – not a pill every day like older medicines. That's great for people who forget daily pills or feel embarrassed taking them. And it's almost 100% effective at stopping HIV in adults and teens. But there's a big problem: the cost. In the US, it sells for over ₹23 lakh a year! Even rich countries find that hard to afford. The company that makes it, Gilead, is working with more than 100 poorer countries to help them make cheaper versions. Still, many African countries where HIV is most common may struggle to get it to the people who need it most. Scientists have been trying to create a proper HIV vaccine for decades, but HIV keeps mutating – changing too fast for one shot to work. New mRNA vaccines (like the ones used for Covid) are being tested, but funding cuts in the US have slowed down this research. That's why lenacapavir gives us hope. But hope only works if everyone, everywhere, can afford it. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Time of India
7 hours ago
- Time of India
Tripura CM mulls sex education in Class VIII-XII curriculum
Agartala: Tripura CM on Friday said the state govt is considering the introduction of sex education in the curriculum for students in Classes VIII to XII. Speaking at the legislative forum in the state assembly, Saha emphasised the importance of this initiative, stating, "We are considering incorporating sex education and HIV/AIDS awareness in the school curriculum in Class VIII-XII. Tired of too many ads? go ad free now This is not a matter of controversy, it is a necessity." He also encouraged community involvement, suggesting that MLAs could allocate funds to support HIV/AIDS patients. Saha highlighted the equal impact of HIV/AIDS on both boys and girls and stressed the importance of engaging youth in sports, cultural activities, and other creative pursuits to steer them away from drug addiction and reduce their vulnerability to HIV/AIDS. He said Tripura was the first state in India to introduce Red Ribbon Clubs in schools and plans to create youth ambassadors to lead campaigns against drug abuse. Expressing concern over the rising number of HIV/AIDS cases and injecting drug users, particularly among teenagers, Saha said an average of 120 new HIV infections are reported each month in the state, despite preventive efforts by the state AIDS Control Society. In response to a proposal by Congress legislator Sudip Roybarman, the chief minister supported the idea of adding a dedicated chapter on sex education and HIV/AIDS to the school curriculum to raise awareness among the most vulnerable age group. Additionally, he suggested that each MLA could allocate Rs 1 lakh per year from their area development fund for initiatives against drugs and HIV.
